VolitionRx Transforms Cancer Blood Tests with 99% Pure DNA Isolation
Gembloux, Wednesday 18 March 2026
VolitionRx has successfully isolated over 99% pure cancer DNA from blood samples. This unprecedented breakthrough promises to revolutionise early cancer detection and significantly advance precision medicine.
A Technical Leap in Liquid Biopsy
For years, the life sciences sector has grappled with a fundamental obstacle in liquid biopsy development: the vast majority of circulating cell-free DNA (cfDNA) in blood plasma originates from healthy cells, masking the crucial genetic markers of disease [1]. On 17 March 2026, VolitionRx Limited detailed a robust solution to this physiological noise, unveiling a proprietary two-step methodology dubbed Capture-Seq™ [1]. By combining physical enrichment with the bioinformatic removal of non-tumour cfDNA sequences, the company has successfully generated circulating tumour-derived DNA (ctDNA) sequencing data sets that exceed 99 percent purity [1]. Dr Jake Micallef, Chief Scientific Officer at VolitionRx, characterised the achievement as a long-term goal for the industry and potentially the most significant scientific breakthrough in cancer testing and monitoring in recent years [1].
Clinical Validation and Diagnostic Accuracy
The transition from laboratory theory to clinical application relies heavily on rigorous validation [GPT]. Early blinded validation results for VolitionRx’s new methodology have shown highly promising diagnostic accuracy [1]. In a primary independent cohort comprising a total of 70 participants, the technology successfully detected all 49 cancers, which included 23 early-stage (I/II) cases, while registering zero false positives among the 21 control subjects [1]. A subsequent blinded cohort reinforced these findings, successfully identifying 13 out of 14 later-stage cancers—an impressive detection rate of 92.857 percent—alongside 10 additional controls [1].
Market Dynamics and the Lab-to-Market Transition
As VolitionRx navigates the critical lab-to-market transition, the commercial stakes are substantial. The company is targeting a Total Addressable Market (TAM) estimated at $36 billion for early cancer detection and MRD monitoring [2]. The broader global liquid biopsy market is already forecast to expand at double-digit growth rates through to the end of the decade [3]. To accelerate the commercialisation of Capture-Seq™, VolitionRx is currently engaged in active discussions with several major global diagnostic and liquid biopsy companies [1][2]. Securing a strategic partnership could prove vital, as the firm remains in a pre-commercial phase in key international markets and relies heavily on equity raises and grants to fund its ongoing operations [3].
Regulatory Milestones and Investment Outlook
Despite the scientific milestones, VolitionRx’s stock (ISIN: US92852X1037) has remained in a holding pattern as of mid-March 2026, with no specific price catalysts emerging in the immediate 48 hours following the technical announcement [3]. The market appears to be awaiting definitive commercial agreements or further peer-reviewed trial data [3]. Dr Elena Voss, a senior biotech equity analyst, observed that investors should closely monitor for trial data releases, as these events historically drive outsized price movements in the micro-cap diagnostics sector [3].